Key considerations when using recombinant DNA-derived factor VIII concentrate (recombinant)

Recombinant DNA-derived coagulation factor VIII concentrate (Altuiiio) is a treatment designed for adults and children with hemophilia type A (congenital factor VIII deficiency) and is widely used for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes, and perioperative bleeding management. However, there are some important things to note when using Altuiiiio to ensure the treatment is safe and effective.

First of all, hypersensitivity reactions are one of the potential risks that require special vigilance when usingAltuiiio. This drug may cause allergic hypersensitivity reactions, including severe anaphylactic shock. If the patient develops any symptoms of allergic reaction during use, such as shortness of breath, wheezing, throat swelling, chest tightness, low blood pressure or itching, he should inform his doctor immediately. Patients who experience symptoms of a hypersensitivity reaction should stop using Altuiio immediately and contact a doctor or seek emergency care so that potential crisis situations can be dealt with promptly.

Secondly, another issue that needs attention is the formation of neutralizing antibodies. After using Altuiiiio, neutralizing antibodies against FVIII may appear, which may affect the effectiveness of treatment. If the patient's bleeding is not effectively controlled, or if the plasma FVIII level does not rise as expected, neutralizing antibody testing is recommended. This test can help doctors evaluate the effectiveness of treatment and decide whether medication needs to be adjusted or other measures taken.

In addition, patients should be monitored regularly while receivingAltuiiio treatment to ensure the effectiveness and safety of the treatment. Maintaining good communication with doctors and reporting any discomfort or abnormal reactions in a timely manner can help doctors better adjust treatment plans and ensure that patients get the best treatment results.

In short, althoughAltuiiio has shown good efficacy in the treatment of hemophilia A, caution still needs to be used during use. Patients should fully understand the risks of possible hypersensitivity reactions and the formation of neutralizing antibodies, follow the doctor's guidance, and conduct relevant monitoring in a timely manner. Through rational medication use and effective communication, risks can be minimized, treatment success rates can be increased, and patients' quality of life can be improved.

Reference link: https://www.drugs.com/altuviiio.html